Prostate Cancer Therapy Targets Cancer Stem Cell Antigen

Prostate Cancer Therapy Targets Cancer Stem Cell Antigen
shutterstock_158643686In a recent study entitled “Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM,” published in BMC Immunology by Zhenling Deng and colleagues from the Department of Immunology at Peking Union Medical College in Beijing, China, the team developed a novel adoptive immunotherapy that targeted a specific cancer stem cell antigen: the epithelial cell adhesion molecule (EpCAM). Ex vivo isolation and expansion of autologous or allogeneic tumor-reactive T cells, i.e. adoptive T-cell immunotherapy, has been used to treat cancer patients, proving efficient in the treatment of patients with metastatic melanoma. However, adoptive T-cell therapy is limited since it cannot be done using cells from all cancer patients. In order to expand its use, the therapy was recently improved by introducing antigen receptors into lymphocytes from circulation. Genes encoding T-cell receptors are now isolated from high avidity, tumor-specific T cells or chimeric antigen receptors (CAR) and are introduced in T cells by retroviral or lentiviral vectors. This approach has already been tested in several clinical trials as a potential alternative therapy for human cancers such as ly
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *